Three inhibitors ALK-inhibitors have been assessed in six randomised phase III trials in patients with advanced anaplastic lymphoma kinase (ALK) positive Non Small-Cell Lung Cancer (NSCLC). Patient and tumour characteristics, efficacy, and safety results are summarised in Tables 1, 2, and 3, respectively. Progression-free survival was the primary endpoint in all trials. In first-line, alectinib was superior to crizotonib, and both crizotinib and ceritinib were superior to pemetrexed plus platinum. Crizotinib and ceritinib were superior to pemetrexed or docetaxel in previously treated patients.
(BELG J MED ONCOL 2018;12(6):275–278)